期刊论文详细信息
Clinical and Experimental Rheumatology
Takayasu arteritis: epidemiological, clinical, and immunogenetic features in Greece
G.K. Bertsias1  C.P. Mavragani1  A.A. Drosos1  D.T. Boumpas1  H.D. Kritikos1  Z.T. Karageorgaki1  M. Spyropoulou-Vlachou1  H.M. Moutsopoulos1 
关键词: Takayasu arteritis;    stenosis;    aneurysm;    HLA.;   
DOI  :  
学科分类:医学(综合)
来源: Pacini Editore SpA
PDF
【 摘 要 】

OBJECTIVES:Takayasu arteritis (TA) is an uncommon disease with clinical heterogeneity across different ethnic groups. We aimed to evaluate the epidemiological, clinical, and immuno-genetic features of TA in Greece.METHODS:Demographic, clinical, laboratory, angiographic, and therapeutic data of 42 patients from 4 large referral centers were retrieved. Serology and Human Lymphocyte Antigen (HLA) typing was performed in 22 patients.RESULTS:We studied 37 women and 5 men with a median age of 31 years at disease onset. Median delay in diagnosis was 24 months and median follow-up was 47 months (range 0-178). Constitutional or musculoskeletal symptoms were present in 86%, especially early in the disease course. Vascular findings were universal with reduced or absent pulse being the most common manifestation (98%). Hypertension was frequent (78%). Extensive disease prevailed and stenotic lesions were more common than aneurysms (95% vs. 40%). Erythrocyte sedimentation rate and C-reactive protein showed modest correlation with disease activity. HLA-B52 was expressed by 37% of the patients vs. 2.4% of the controls (p<0.001). Glucocorticoids and cytotoxic agents were used in most patients with remission rates of 83%. A total of 42 surgical procedures were performed with success rates of 87%.CONCLUSIONS: TA in Greece clinically and epidemiologically resembles the pattern of disease in Japan and the Western hemisphere. There is considerable delay in diagnosis, which may partially reflect failure to recognize a rare disease. New surrogate markers are needed to assess disease activity. Glucocorticoids are the cornerstone of treatment and cytotoxic drugs are frequently used as steroid sparing agents.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201912020416608ZK.pdf 398KB PDF download
  文献评价指标  
  下载次数:30次 浏览次数:5次